Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis

Study information

Needs review

study design

laboratory experiment

Citation

PMID PubMed identifier for scientific articles.

32711581

DOI Digital object identifier for electronic documents.

10.1186/s40168-020-00886-x

URI

Authors

Zhang P, Liu J, Xiong B, Zhang C, Kang B, Gao Y, Li Z, Ge W, Cheng S, Hao Y, Shen W, Yu S, Chen L, Tang X, Zhao Y, Zhang H

Journal

Microbiome

Year

2020

Keywords:

Alginate oligosaccharides, Busulfan, Correlation, Fecal microbiota transplantation, Metabolome, Mucositis, Rescue

BACKGROUND: The increasing incidence of cancer and intestinal mucositis induced by chemotherapeutics are causing worldwide concern. Many approaches such as fecal microbiota transplantation (FMT) have been used to minimize mucositis. However, it is still unknown whether FMT from a donor with beneficial gut microbiota results in more effective intestinal function in the recipient. Recently, we found that alginate oligosaccharides (AOS) benefit murine gut microbiota through increasing "beneficial" microbes to rescue busulfan induced mucositis. RESULTS: In the current investigation, FMT from AOS-dosed mice improved small intestine function over FMT from control mice through the recovery of gene expression and an increase in the levels of cell junction proteins. FMT from AOS-dosed mice showed superior benefits over FMT from control mice on recipient gut microbiotas through an increase in "beneficial" microbes such as Leuconostocaceae and recovery in blood metabolome. Furthermore, the correlation of gut microbiota and blood metabolites suggested that the "beneficial" microbe Lactobacillales helped with the recovery of blood metabolites, while the "harmful" microbe Mycoplasmatales did not. CONCLUSION: The data confirm our hypothesis that FMT from a donor with superior microbes leads to a more profound recovery of small intestinal function. We propose that gut microbiota from naturally produced AOS-treated donor may be used to prevent small intestinal mucositis induced by chemotherapeutics or other factors in recipients. Video Abstract.

Experiment 1

Edit History Delete

Mark reviewed

Your review change was submittedDuplicate this Experiment Add a new Signature

Needs review

Curated date: 2024/11/05

Curator: Tosin

Revision editor(s): Tosin

Subjects

Location of subjects: China

Host species Species from which microbiome was sampled. Contact us to have more species added.: Mus musculus

Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology: Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology: Mucositis Mucositis,mucositis

Group 0 name Corresponds to the control (unexposed) group for case-control studies: BA0

Group 1 name Corresponds to the case (exposed) group for case-control studies: BA10

Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group: Treatment group for mice injected with 40 mg/kg BW (body weight) busulfan once then dosed with 10 mg/kg BW (body weight) AOS(alginate oligosaccharide-dosed.

Group 0 sample size Number of subjects in the control (unexposed) group: 15

Group 1 sample size Number of subjects in the case (exposed) group: 15

Lab analysis

Sequencing type: 16S

16S variable region One or more hypervariable region(s) of the bacterial 16S gene: V3-V4

Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance: Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).: relative abundances

Statistical test: LEfSe

Significance threshold p-value or FDR threshold used for differential abundance testing (if any): 0.05

MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?: No

LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool: 4

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness: unchanged

Chao1 Abundance-based estimator of species richness: unchanged

Signature 1

Edit History Delete

Mark reviewed

Your review change was submitted

Needs review

Curated date: 2024/11/05

Curator: Tosin

Revision editor(s): Tosin

Source: Figure 1d

Description: Significant different taxa between BA0 and BA10.

Abundance in Group 1: increased abundance in BA10

NCBI	Quality Control	Links
Aerococcaceae
Aerococcus
Bacteroidaceae
Bacteroides
Bacteroides ovatus
Enterobacterales
Enterobacteriaceae
Escherichia
Escherichia coli

Revision editor(s): Tosin

Signature 2

Edit History Delete

Mark reviewed

Your review change was submitted

Needs review

Curated date: 2024/11/05

Curator: Tosin

Revision editor(s): Tosin

Source: Figure 1d

Description: Significant different taxa between BA0 and BA10.

Abundance in Group 1: decreased abundance in BA10

NCBI	Quality Control	Links
Deferribacteraceae
Deferribacterales
Deferribacteres
Mucispirillum
Mucispirillum schaedleri

Revision editor(s): Tosin

Experiment 2

Edit History Delete

Mark reviewed

Your review change was submittedDuplicate this Experiment Add a new Signature

Needs review

Curated date: 2024/11/05

Curator: Tosin

Revision editor(s): Tosin

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies: A10-FMT (fecal microbiota transplantation)

Group 1 name Corresponds to the case (exposed) group for case-control studies: A100-FMT (fecal microbiota transplantation)

Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group: Mice treated with busulfan and FMT (fecal mcrobiota transplantation) from the AOS 100 mg/kg group.